KLF7 is a zinc finger transcription factor that functions as a pleiotropic regulator in both normal physiology and disease. Mechanistically, KLF7 acts as a transcriptional activator that binds to promoter and super-enhancer regions of target genes 123. In normal tissues, KLF7 plays critical roles in neuronal morphogenesis and metabolic regulation, including modulation of insulin sensitivity and repression of adipogenesis [UniProt annotation]. However, KLF7 has emerged as a significant oncogenic driver across multiple cancer types. In hepatocellular carcinoma, HMGB1-mediated KLF7 elevation promotes metastasis through transactivation of TLR4 and PTK2, forming a positive feedback loop 4. KLF7 also drives HCC progression via the KLF7/SLC1A5 axis by regulating tryptophan metabolism and serotonin production 2. In head and neck squamous cell carcinoma, KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote tumorigenicity and metastasis 1. In oral cancer, KLF7 maintains cancer stem cell stemness through ITGA2 regulation and promotes epithelial-mesenchymal transition via snail induction 56. In colon adenocarcinoma, KLF7 activates PDGFB signaling to promote progression 3. A KLF7 SNP (rs2302870) associates with reduced coronary artery disease risk 7, suggesting protective effects in cardiovascular disease. These findings identify KLF7 as a therapeutic target across multiple malignancies.